LEADER 01730oam  2200481 a 450 
001 9910698508903321
005 20090619110149.0
035   $a(CKB)3460000000108636
035   $a(OCoLC)274128841
035   $a(EXLCZ)993460000000108636
100   $a20081119d2008      ua             0
101 0 $aeng
135   $aurbn|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aExamining the implications of drug importation$b[electronic resource] $ehearing before the Committee on the Judiciary, United States Senate, One Hundred Eighth Congress, second session, July 14, 2004
210  1$aWashington :$cU.S. G.P.O.,$d2008.
215   $aiv, 278 pages $cdigital, PDF file
225 1 $aS. hrg. ;$v108-923
300   $aTitle from title screen (viewed on Nov. 19, 2008).
300   $a"Serial no. J-108-89."
320   $aIncludes bibliographical references.
517   $aExamining the implications of drug importation 
606   $aDrug reimportation$zUnited States
606   $aProduct counterfeiting$zUnited States
606   $aImports$xLaw and legislation$zUnited States
606   $aConsumer protection$zUnited States
606   $aForeign trade regulation$zUnited States
606   $aPharmaceutical policy$zUnited States
615  0$aDrug reimportation
615  0$aProduct counterfeiting
615  0$aImports$xLaw and legislation
615  0$aConsumer protection
615  0$aForeign trade regulation
615  0$aPharmaceutical policy
801  0$bGPO
801  1$bGPO
801  2$bGPO
906   $aBOOK
912   $a9910698508903321
996   $aExamining the implications of drug importation$93466624
997   $aUNINA